Biosency
Biosency is dedicated to improving the management of respiratory patients through innovative digital solutions. They develop predictive telemonitoring tools, including Bora care®, which supports early detection and prevention of COPD exacerbations, enhancing patient care and reducing healthcare costs. Their solutions are clinically validated, certified, and integrate advanced data analysis and real-time monitoring to facilitate personalized and proactive healthcare.
Industries
Nr. of Employees
small (1-50)
Biosency
13 Rue Claude Chappe – Bât A Oxygène, 35510 Cesson-Sévigné
Patents
Monitoring device for monitoring a physiological parameter and methods thereof
US-12274534-B2
View Details
Monitoring device for monitoring a physiological parameter and methods thereof
US-12274534-B2
View DetailsProducts
Integrated remote monitoring solution for COPD
An end‑to‑end remote monitoring service combining wearable vital-sign sensing, device telemetry ingestion, predictive analytics and a clinical dashboard to support proactive management of COPD patients.
Ventilator monitoring module
Module that collects and displays parameters from ventilators, supports combinable alerts and configurable thresholds, and is aligned with national reimbursement frameworks.
Wrist-worn vital-sign sensor
Lightweight, discreet wearable designed for continuous daily life monitoring with clinical-grade measurement claims and defined battery autonomy and ingress protection.
Integrated remote monitoring solution for COPD
An end‑to‑end remote monitoring service combining wearable vital-sign sensing, device telemetry ingestion, predictive analytics and a clinical dashboard to support proactive management of COPD patients.
Ventilator monitoring module
Module that collects and displays parameters from ventilators, supports combinable alerts and configurable thresholds, and is aligned with national reimbursement frameworks.
Wrist-worn vital-sign sensor
Lightweight, discreet wearable designed for continuous daily life monitoring with clinical-grade measurement claims and defined battery autonomy and ingress protection.
Services
Implementation and configuration of cloud-based remote monitoring platforms, dashboard setup, alert parametrization and integration with local clinical workflows.
Design and conduct of clinical and post‑market studies, performance validation versus reference standards, and support for publication and regulatory submissions.
Provision of SDKs/APIs and technical support to integrate wearable and device telemetry into third‑party monitoring platforms and electronic systems.
Implementation of data protection measures, HDS-certified hosting, encryption, and support for GDPR and national certification conformance.
Implementation and configuration of cloud-based remote monitoring platforms, dashboard setup, alert parametrization and integration with local clinical workflows.
Design and conduct of clinical and post‑market studies, performance validation versus reference standards, and support for publication and regulatory submissions.
Provision of SDKs/APIs and technical support to integrate wearable and device telemetry into third‑party monitoring platforms and electronic systems.
Implementation of data protection measures, HDS-certified hosting, encryption, and support for GDPR and national certification conformance.
Expertise Areas
- Remote patient monitoring for chronic respiratory disease
- Predictive analytics for COPD exacerbation
- Wearable sensor development and validation
- Clinical trial management and real‑world evidence generation
Key Technologies
- Photoplethysmography-based SpO2 and heart rate sensing
- Respiratory rate extraction algorithms
- Machine learning / semi‑supervised learning for physiological prediction
- Cloud-based clinical data platform (web and mobile)
News & Updates
Study results presented at ATS 2023 show that Biosency's BVS3 algorithm predicts exacerbations with 86% accuracy, 3 days prior to hospitalization.
The company has received multiple awards including the i-Lab laureate, i-Nov trophy, and Bretagne impact awards, recognizing its innovation in health technology.
At ERS 2023, Biosency presented clinical study results demonstrating the predictive power of their BVS3® score for COPD exacerbations, predicting 86% of cases 3 days in advance.
i-Lab Laureate 2018
Biosency was awarded the i-Lab prize for innovative technology projects in France.
i-Nov Trophy 2020
Recognition for their innovative deeptech project supported by the French government.
CE MDR Certification 2023
Certification of their medical device solutions according to European standards.
Study results presented at ATS 2023 show that Biosency's BVS3 algorithm predicts exacerbations with 86% accuracy, 3 days prior to hospitalization.
The company has received multiple awards including the i-Lab laureate, i-Nov trophy, and Bretagne impact awards, recognizing its innovation in health technology.
At ERS 2023, Biosency presented clinical study results demonstrating the predictive power of their BVS3® score for COPD exacerbations, predicting 86% of cases 3 days in advance.
i-Lab Laureate 2018
Biosency was awarded the i-Lab prize for innovative technology projects in France.
i-Nov Trophy 2020
Recognition for their innovative deeptech project supported by the French government.
CE MDR Certification 2023
Certification of their medical device solutions according to European standards.